Aktie A14U12 ALLERGAN PLC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Allergan plc

Aktien

A14U12

IE00BY9D5467

AGN

Verzögert Nyse
Andere Börsenplätze
 		% 5 Tage % 1. Jan.
- USD -.--% Intraday Chart für Allergan plc +1.73% +0.97%
05.03. Allergan Aesthetics gibt die FDA-Zulassung von JUVEDERM VOLUMA XC für die Injektion in die Schläfenregion zur Verbesserung mittelschwerer bis schwerer Schläfenhohlräume bei Erwachsenen über 21 Jahren bekannt CI
2023 Allergan Aesthetics gibt positive Topline-Ergebnisse der zweiten Phase-3-Studie zu Onabotulinumtoxina für die Behandlung von Platysma-Prominenz bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement
Allergan Aesthetics Announces the U.S. FDA Approval of JUVEDERM VOLUMA XC for Injection in the Temple Region to Improve Moderate to Severe Temple Hollowing in Adults over the Age of 21
Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumtoxina for the Treatment of Platysma Prominence
Allergan Aesthetics Announces the Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BotoX®? Cosmetic)
Allergan plc Announces U.S. FDA Approval of SKINVIVE™ by JUVÉDERM®
Allergan Aesthetics Announces the Highly Anticipated National Launch of Juvéderm® Volux™ Xc
Allergan Aesthetics Announces the Launch of the Long-Awaited SkinMedica Even & Correct Collection
Allergan Aesthetics to Present Data from Its Leading Aesthetic Portfolio At the 2022 American Society for Dermatologic Surgery Meeting
Allergan Aesthetics Announces the Launch of SkinMedica Firm & Tone Lotion for Body
FDA Approves JUVÉDERM® VOLUX™ XC for Improvement of Jawline Definition
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision
PatientFi Expands Partnership with Allergan Aesthetics
AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.
Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available
Allergan Aesthetics to Present Data from its Aesthetic Portfolio at the 2021 American Society for Dermatologic Surgery Virtual Meeting
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
Allergan, an AbbVie Company, to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopia
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A14U12 Aktie
  4. Nachrichten Allergan plc
  5. Andere Sprachen